Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Capsigen

- PMLiVE

New data shows benefits for presymptomatic SMA patients treated with Zolgensma

Zolgensma was initially approved in 2019 for the treatment of SMA, launching with a list price of $2.125m

- PMLiVE

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen has initiated the late-stage study based on positive results from the phase 2 LILAC study

Biogen Idec building

Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease

The drug failed to meet the primary efficacy endpoint in a phase 2 study

- PMLiVE

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies

- PMLiVE

Biogen reports new data backing long-term benefit of Spinraza

Company also revealed new analysis suggesting benefits associated with a higher therapy dose

Biogen Idec building

Biogen to begin shipping newly approved Alzheimer’s treatment in two weeks

Just days after the drug was approved by the FDA advisory panel, two of its members have resigned

- PMLiVE

FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision

FDA is requiring Biogen to conduct a new randomised, controlled clinical trial to verify the drug’s clinical benefit for Alzheimer’s patients

- PMLiVE

Sarepta Therapeutics’ DMD gene therapy shows early success

Most patients with Duchenne muscular dystrophy require full-time use of a wheelchair by their early teens

Biogen Idec building

Biogen and Envisagenics to advance RNA splicing research for CNS diseases

Envisagenics’ SpliceCore platform can be used to identify, test and validate RNA splicing errors at scale

- PMLiVE

Biogen and Capsigen to collaborate on gene therapies

Biogen will gain exclusive right for undisclosed number of CNS and neuromuscular disease targets

- PMLiVE

Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

Trial pause follows reports of three cases of peripheral neuropathy in phase 1 study

Biogen Idec building

Biogen to open compassionate use programme for ALS patients with ‘rapidly progressive disease’

Move comes after mounting pressure from patients and campaigners

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links